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Abstract
Background: Treatment of maternal iron-deficiency anaemia can reduce risks of prematurity and low birth weight;
hence a reliable diagnosis of maternal iron needs is critical. However, erythrocyte indices and serum ferritin have
shown a weak correlation with iron status during pregnancy. This study verified the accuracy of those tests to
predict the responsiveness to a therapeutic test with oral iron as reference standard for iron deficiency in pregnant
women.
Methods: A prospective diagnostic study phase 3 was conducted in a single prenatal care center in Northeast
Brazil. Between August 2011 and October 2012 a consecutive sampling included 187 women in their 2nd-3rd
trimesters of low-risk pregnancy and having anaemia (haemoglobin <11.0 g/dL). Until December 2012, 139 women
completed a trial with daily pills of ferrous sulfate (40 mg of iron), during 23 to 125 days. Haemoglobin (Hb), other
erythrocyte indices and ferritin (index-tests) were assessed pre-treatment by automated analyzers. Hb was
performed also post-treatment to assess the therapeutic response by its post-pretreatment differences. We
estimated sensitivity (Se), specificity (Sp), predictive values (PV), likelihood ratios (LR), diagnostic Odds Ratio (OR),
area under Receiver Operating Characteristic curve (AUC), accuracy ratio and agreement coefficient of the index-
tests against an increase of at least 0.55 Hb Z-score (reference standard test). We calculated the Z-scores according
to the reference population from Centers for Disease Control and Prevention.
Results: Hb had a mean increase of 0.24 Z-score after 30 iron pills (p 0.013). All index-tests demonstrated PV- above
70 %, PV+ around 40 %, LR around 1.0, and AUC of 0.5 to 0.6. Hb and haematocrit had Se of 50 % (95 % CI 40 to
70); and Sp of 59 % (95 % CI 43 to 74) and 47 % (95 % CI 38 to 57), respectively. Ferritin, Mean Corpuscular Volume,
Mean Corpuscular Haemoglobin, Mean Corpuscular Haemoglobin Concentration and Red blood cell Distribution
Width had Se below 40 % with Sp above 70 %.
Conclusions: Erythrocyte indices and ferritin could not predict the iron needs of anemic pregnant women.
Increases of Hb Z-scores after a short treatment with oral iron may be a reliable therapeutic test.
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Background
A reliable diagnosis of maternal iron-deficiency is a crit-
ical issue, since an effective therapy with oral iron during
pregnancy can prevent perinatal adverse outcomes, such
as low birth weight [1, 2] and prematurity [2]. The pres-
ence of anaemia, in other words, low levels of haemoglo-
bin concentration (Hb) or haematocrit (HTC), has been
considered as a proxy for iron-deficiency and widely
used to estimate its prevalence and to indicate and
evaluate the iron-therapy during pregnancy [3, 4], espe-
cially in developing countries [4, 5]. However, maternal
anaemia may also be associated with infectious or nutri-
tional diseases and gestational haemodilution [4], as well
as the iron-deficiency may be present with normal levels
of Hb and HTC [3, 6]. Serum ferritin is the most recom-
mended iron status biomarker [3, 4], but it has an iron-
storage role rather than functional [6, 7]. Actually, there
is a lack of standardized and validated diagnostic screen-
ings to select pregnant women for iron-therapy in clin-
ical trials [8], and so it allows one to question whether
iron needs are being correctly identified and treated dur-
ing pregnancy.
Clinical studies have showed a low accuracy of these
tests to diagnose maternal iron-deficiency [9–11]. Hb and
HTC [9, 12–14], as well as the other erythrocyte indices
[9, 13], do not correlate with the iron status in pregnant
women, probably due to the physiological haemodilution
[15, 16] and ‘emergency hemopoiesis’ [17, 18], which not
only modify the cell indices in the erythrogram, but also
the serum ferritin and other biomarkers of the body iron
[6, 7]. The cutoff points of erythrocyte indices and serum
ferritin were based on the distribution curves of popula-
tions from developed countries in the 70’s and 80’s [19,
20]; therefore, they were not defined by diagnostic valid-
ation studies. Pregnancy validation studies, which com-
pared erythrocyte indices with the serum ferritin [9, 10,
14, 21, 22] or the iron content in the bone marrow [11,
12] describe very low sensitivity (Se) and/or specificity
(Sp) for the erythrocyte mass indices (Hb and HTC) [10,
14, 21, 22] and morphology indices (mean corpuscular
volume - MCV, mean corpuscular haemoglobin - MCH,
mean corpuscular haemoglobin concentration - MCHC,
red blood cell distribution width - RDW) [9, 11, 12, 22].
On the other hand, only two studies compared the ferritin
levels with the iron in pregnant women’s bone marrow
[11, 12], and there is no consensus about its cutoff during
pregnancy [7, 23–25].
Thus, a large proportion of pregnant women is suscep-
tible to diagnostic misclassification and decision-making
mistakes when the indication of iron-therapy is based on
the erythrogram or even ferritin results. Studies which
validate those tests against therapeutic outcomes of iron
supplementation at a real clinical setting might support
this assertion. Therefore, our study assessed the diagnos-
tic performance of erythrocyte indices and serum ferritin
to predict and discriminate the increase of Hb in re-
sponse to a therapeutic test with oral iron, which was
applied as the reference standard of iron-deficiency in
anaemic pregnant women at a prenatal care center. The
response to iron-therapy may be a suitable diagnostic al-
ternative, as is being recommended by World Health
Organization (WHO) [3] and British Committee for
Standards in Haematology [25]. To normalize the effect
of haemodilution phenomenon on Hb changes [26], we
adjusted the Hb values for the gestational age at start
and end of iron-therapy, and we are introducing a
Nomogram of Hb Z-scores as an easy-to-use graphic to
follow the Hb values during pre-natal care.
Methods
This is a prospective validation study on phase III [27],
whose index-tests were the pre-treatment values of
serum ferritin, red blood cell count, Hb, HTC, MCV,
MCH, MCHC, RDW and reticulocyte count, and refer-
ence standard was the responsiveness to a therapeutic
test with oral iron. This report was made according to
the requirements of the Standards for Reporting of Diag-
nostic Accuracy Initiative [28]. The validation studies on
phase III are conducted with a population in whom it is
clinically sensible to suspect the target disease in a prag-
matic real-world setting of routine clinical practice [27].
Thereby, this study was conducted at a single pre-natal
care center and compared the diagnostic tests in preg-
nant women previously classified as anemic, as they are
under higher risk of iron-deficiency.
This study followed the ethics principles in research
with human beings of the World Medical Association’s
Declaration of Helsinki, and was approved by the Re-
search Ethics Committee of IMIP (registration number
2050/10). Each participant was oriented, read and signed
the consent form prior to their inclusion in the study.
As we applied a before-after intervention with medicinal
iron, our protocol was inscribed in International Clinical
Trials Registry Platform (U1111-1123-2605) of WHO,
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and in Brazilian Registry of Clinical Trials (RBR-237 reg-
istered 28 July 2011, available at: http://www.ensaioscli-
nicos.gov.br/rg/RBR-237wbg).
Participants and follow-up
Pregnant women attended at the prenatal care center
of Instituto de Medicina Integral Prof Fernando Fig-
ueira (IMIP) were consecutively recruited based on a
Hb value < 11 g/dL (WHO criteria for anaemia) [5] in
the routinely prenatal exams plus the following inclu-
sion criteria: 18 to 35 years old, 12th to 32nd weeks of
low-risk singleton pregnancy. Our prenatal service
composes of the reference network assistance for
pregnant women in the public health system in the
state of Pernambuco, in the Northeast of Brazil, and
performs an average of 17,000 outpatient consulta-
tions and 6,000 deliveries per year. The exclusion cri-
teria were Hb ≤ 7.0 g/dL, history of hypersensitivity or
intolerance to ferrous sulfate, disorders or mental def-
icits; use of tobacco, alcohol or other drugs; previous
diagnosis of another cause of anaemia; or infection at
the time of the enrollment (positive serology for Hu-
man Immunodeficiency Virus or syphilis, leukocytosis
or leukocyturia with positive urine culture, clinical
signs and symptoms of airway infection).
Between August 2011 and October 2012, 187 women
were consecutively enrolled and evaluated monthly for a
period of 23 to 125 days, hence until December 2012,
139 women completed the trial. Sociodemographic in-
formation (age, self-assigned ethnicity, county of resi-
dence, educational level, family income per capita) and
clinical-obstetric data (body mass index-BMI, numbers
of pregnancies and births, time since the last delivery,
weeks of current pregnancy and recent use of oral iron)
were obtained at the time of the enrollment, and after
the women were forwarded to blood collection to meas-
ure erythrocyte indices and serum ferritin pre-treatment
(index-tests).
Every month, in addition to the routine of prenatal
care, the participants responded a questionnaire about
adverse effects (anorexia, heartburn, nausea, vomiting,
diarrhea, constipation, colic or abdominal pain) and ad-
herence to therapy, while the iron pills not taken were
counted; and after they were forwarded to a new blood
collection to measure the Hb post-treatment (follow-up
of responsiveness to iron-therapy). The withdrawal oc-
curred in case of high-risk pregnancy, genital bleeding,
drop out of treatment or intolerance, and use of other
iron supplements. The follow-up was stopped in case of
childbirth, and cure (Hb ≥ 11.0 g/dL) or worsening of
anaemia (Hb < 7.0 g/dL or drop in Hb > 1.0 g/dL). For
more details, the protocol was previously published
under the acronym AMA (it can be seen in supplemen-
tary material of this article - Additional file 1) [29].
Test methods
The index-tests (erythrocyte indices and serum ferritin)
and the reference standard test (therapeutic test with
oral iron) were prospectively performed in all partici-
pants. The therapeutic test with oral iron began within
the first 24 h after the blood collection for index-tests
measures and consisted of two pills per day of ferrous
sulfate with 40 mg of elemental iron (an algorithm of
procedures and follow-up of the study can be seen in
supplementary material of this article - Additional file 2).
The responsiveness to the therapeutic test with oral
iron was measured in Z-scores of Hb, according to the
method proposed by Beaton and McCabe [26] to
normalize the haemodilution phenomenon. Each ob-
served Hb value was converted, subject by subject, into
standard deviation (SD) from the reference mean ex-
pected for the gestational week at the moment of the
blood sampling. We used reference means of Hb re-
ported by Centers for Disease Control and Prevention
(CDC) [19, 20], which are based on the distribution of
values of Hb in iron-supplemented and well-nourished
pregnant women from developed countries. The criteria
to define a positive reference standard test was defined a
priori based on a theoretic rationale [29], as empirical
data are rare. Anaemia was classified as iron-responsive
by an Hb Z-score increase of at least 0.55 SD at the end
of the intervention (difference between post and pre-
treatment Hb Z-scores). This way, the reference stand-
ard results were obtained 23 to 125 days after the deter-
mination of the index-tests, which assured the blinding
and the independence between them. The rationale used
in developing our criteria on reference standard is de-
scribed in details in our published protocol [29].
The erythrograms were analyzed by using the flow cy-
tometry and absorbance with the automated hematology
analyzer ABX Pentra DF120 manufactured by Horiba® and
complemented by microscopic reading of smear stained
with panoptic dye. This automated analyzer performs
automatic calibration, validation and standardization for
each sample tested. The reticulocyte counts were per-
formed manually through the reading of blood smear
stained with brilliant cresyl blue dye. The serum ferritin
levels were obtained using the chemiluminescence im-
munoassay method with ADVIA equipment Centaur
Ferritin, manufactured by Bayer®, whose detection limits
are from 1 to 1650 ng/mL and the reference interval is of
10 to 291 ng/mL. The calibration of this immune assay is
carried out according to the 2nd international standard of
WHO (WHO 80/578) [30].
The blood samples were collected and processed by
the routinely procedures of the laboratory service of
IMIP, which have governmental certification and follow
standardized operational norms. The accuracy analysis
was performed by applying the cutoff points of WHO
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for the 2nd trimester of pregnancy [3], which correspond
to two SD below the mean from the CDC [19, 20] refer-
ence population: red blood cell count < 3.8•1012cells/L;
Hb < 10.5 g/dL; HTC < 32.0 %; MCV < 81.0 fL; MCH <
26.0 pg; MCHC < 32.0 g/dL; RDW > 14.0 %; reticulocyte
count < 1.0 %; serum ferritin < 12.0 ng/mL.
Sample size and data analysis
The sample size was calculated accounting for a sensitiv-
ity of 90 %, a specificity of 80 % and a maximum relative
error of 10 %, resulting in a sample size comprised of 43
cases (iron-responsive anaemia) and 97 non-cases (not
iron-responsive anaemia); but after the end of the study
we had 37 cases plus 102 non-cases due to five exclu-
sions a posteriori.
The data were double entered and validated using the
Epi Info 3.5.4, and were analyzed with the software
Stata/SE 12.1 and Open Epi 2.3.1. A dose-response effect
of each iron pill ingested on the Hb Z-scores was veri-
fied in a linear regression model adjusted for days of
treatment, laboratorial characteristics (initial values of
Hb and serum ferritin) and other studied co-variables
(sociodemographic, clinical-obstetric and therapeutic).
These study population characteristics were compared
between the two groups of cases and non-cases, using
the Student’s t-test, Pearson’s Chi-square, Mann-
Whitney test and Fisher’s exact test, considering a
significance level of 5 %.
The diagnostic accuracy of erythrocyte indices and
serum ferritin was estimated by calculating the sensitiv-
ity (Se), specificity (Sp), positive predictive value (PPV)
and negative (NPV), positive likelihood ratio (LR+) and
negative (LR-), diagnostic Odds Ratio (OR), area under
the ROC curve (AUC), accuracy ratio and Cohen’s
kappa coefficient (inter-rater agreement), and their re-
spective confidence intervals of 95 %.
Briefly, the likelihood ratio is a probability quotient of a
positive (LR+) or a negative (LR-) result between individ-
uals with and without the target disease; so, the higher LR
+ (over 1.0) more informative is a positive result for pres-
ence of the disease, while the lower LR- (under 1.0) more
informative is a negative result for absence of the disease.
The diagnostic OR is a ratio between both LR+ and LR-,
so the higher OR higher the overall power of the test to
discriminate the presence from the absence of disease
[31]. On the other hand, the Cohen’s kappa coefficient is
the proportion of agreements between index-test and ref-
erence standard, discounting the probability of random
agreements, so the higher this coefficient more accurate is
the index-test in relation to a reference standard; however,
if both index and reference tests are inaccurate this coeffi-
cient can be high but clinically irrelevant [32].
Those pregnant women who did not ingest the total
doses of at least 1200 mg of elemental iron were excluded
from these analyzes. In order to parameterize the asym-
metrical distribution of the serum ferritin values in the
sample, a logarithmic transformation it was performed;
however, the ROC curve with log-transformed values did
not differ from that with absolute values. Finally, as a
study product, we have built a nomogram with hypothet-
ical curves of negative and positive units of Z-scores in re-
lation to the U-shaped curve of reference means of Hb by
CDC at each gestational week (Fig. 1- Nomogram of Hb Z-
scores) [19, 20].
Fig. 1 Nomogram with theoretical Z-scores curves of haemoglobin (Hb) in relation to the mean curve through gestational weeks from a reference
population reported by Centers for Disease Control and Prevention [19, 20]
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Results
Study population characteristics
613 pregnant women with anaemia were identified at the
IMIP laboratory web system and 487 were contacted by the
research team and sought us at the time of their routine
prenatal consultation. Among them, 246 met the inclusion
criteria, but 24 did not accept to participate in the study
and 35 were excluded, totaling a sample of 187 pregnant
women, who were included and followed between August
2011 and December 2012 (a flow diagram showing inclu-
sions, losses and failures to undergo index-testes and
reference-standard test can be seen in the supplementary
material of this article - Additional file 3). There were
25.7 % of losses: 43 follow-up losses and five exclusions for
not taking the minimum effective iron doses (indeterminate
results of the reference standard - Table 2), totaling 37
iron-responsive plus 102 not iron-responsive women.
Women had ingested 31 to 180 iron pills during 23 to
125 days. This period differed of study protocol due to de-
lays between monthly evaluations as they happened at the
routine prenatal care.
The characteristics of the participants are shown in
Table 1, according to the presence or not of responsive-
ness to the therapeutic test with oral iron (reference
standard). Almost all of the pregnant women lived in the
urban area. The sociodemographic and clinical-obstetric
characteristics did not differ and the women using daily
iron supplements for more than 1 month before the
study (n 23) were homogeneously distributed between
the groups.
The laboratory pre-treatment characteristics showed
some differences between the two groups. The means of
Hb and Hb Z-scores were significantly lower in the
group with iron-responsive anaemia; and the median of
serum ferritin levels tended to be lower in this group,
without statistical significance. Regarding to the thera-
peutic characteristics, more than 90 % of the pregnant
women in both groups ingested at least 1,800 mg of
elemental iron until the follow-up end; the gastrointes-
tinal complains were less frequent, while the duration
and the number of iron pills ingested were higher among
not iron-responsive women.
The erythrogram pre-treatment results were obtained
from all participants, however, due to operational problems
of the laboratory facility, 17 women did not have the reticu-
locyte count performed, occurring the same with serum fer-
ritin in seven observations (lost results of index-tests or not
performed in Table 2), which were excluded from each re-
spective analysis. No participant reported adverse events by
performing index-tests, such as local pain or bleeding due
to blood sampling for erythrogram and serum ferritin mea-
surements; but 66 % (92/139) of women complained of
gastrointestinal symptoms after commencing the thera-
peutic test with oral iron.
Parameters of accuracy to predict the presence or
absence of iron-responsive anaemia
Table 3 shows the accuracy parameters of erythrocyte indi-
ces and serum ferritin at the cutoff points recommended by
WHO [3], observing that the PPV were around or below
40 %, while the NPV were all above 70 %. The erythrocyte
mass indices (Hb and HTC) presented Se and Sp of around
50 %; the red blood cell count presented Se of 86 % with Sp
of 22 %, while the reticulocyte count presented Se of 6 %
with Sp of 94 %. The serum ferritin and all the erythrocyte
morphology indices (MCV, MCH, MCHC and RDW) pre-
sented Se below 40 % and Sp above 70 %.
Parameters of accuracy to discriminate between presence
and absence of iron-responsive anaemia
The LR + and LR- presented values very close to 1.0. The
LR+ and LR- were just as close, resulting in diagnostic OR
(ratio LR+ : LR-) slightly above or below 1.0. The AUC of
serum ferritin was 0.61 and of the erythrocyte indices
ranged from 0.51 to 0.64 (Table 4). All index-tests showed
values of diagnostic accuracy (percentage of true tests) be-
tween 39.6 % (for red blood cell count; 95 % CI 31.8 to
47.9) and 69.8 % (for MCHC; 95%CI 61.7 to 76.8). In gen-
eral, there were low rates of agreement between the
index-tests and the reference standard, with the following
values of the Cohen’s kappa test: red blood cell count =
0.05 (95 % CI -0.04 to 0.15); HTC = 0.05 (95 % CI -0.09 to
0.19); Hb = 0.05 (95 % CI -0.09 to 0.20); MCV = 0.06 (95 %
CI -0.10 to 0.22); MCH= 0.07 (95 % CI -0.08 to 0.23);
MCHC= 0.17 (95 % CI 0.00 to 0.33); RDW= -0.03 (95 %
CI -0.19 to 0.14); reticulocyte count = 0.00 (95 % CI -0.12
to 0.12); serum ferritin = 0.08 (95 % CI -0.09 to 0.25).
Therapeutic test with oral iron
There was a mean increase of 0.008 Hb Z-score for each
iron pill (p = 0.013), independently of sociodemographic
and clinical-obstetric characteristics, and pre-treatment
values of serum ferritin and leucocytes, and adjusted for
Hb pre-treatment and duration of treatment. This dose-
response effect was not coincident with case criterion as
we predefined, hence 30 pills of oral iron would result in
an increase of 0.24 Hb Z-score rather than 0.55. For this
reason, we estimated Se, Sp, PPV, NPV, LR and diagnos-
tic OR also using cutoff points of 0.10, 0.20, 0.30 and
0.40 Hb Z-scores, but results were not sensitive to this
criterion changes (see the multiple linear regression and
accuracy reanalysis in supplementary material of this art-
icle - Additional files 4 and 5).
Discussion
Our analysis showed that the serum ferritin (SF) levels
and the values of the erythrocyte indices did not have a
good performance to predict (Se, Sp and PV) and to dis-
criminate (LR, diagnostic OR, accuracy, agreement and
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AUC) the iron-responsiveness among the anemic preg-
nant women studied. All index-tests presented PPV
below 50 %, and the Hb and HTC (the most used
erythrocyte indices) had both Se and Sp very low. The
SF, morphological indices and young red blood cell (re-
ticulocyte count) had low Se with high Sp; while the op-
posite occurred with the mature red blood cell count.
The agreements between the results of any erythrocyte
index or SF and the reference standard were poor
(kappa = 0.00 to 0.19) [32]; and AUC were set in a less
accurate (0.5 < AUC ≤ 0.7) range [33], so even their opti-
mal cutoffs could not result in Se and Sp simultaneously
above 50-60 %. The post-test probabilities of the disease
(PPV) and non-disease (NPV) were close to the pretest
probabilities (frequency) of cases (27 %) and non-cases
(73 %), so a positive or negative result did not add diag-
nostics, as well as it was not an evidence in favor (LR+ >
2.0) or against (LR- < 0.5) the disease, resulting in few in-
formative (OR < 2.0) tests [31].
Previous studies, which validated the erythrocyte indices
against SF at 2nd and 3rd gestational trimesters, report simi-
lar low diagnostic performance with very low Se [14, 21,
22, 34]. Accordingly, in the National Health and Nutrition
Examination Survey of United States (NHANES) 1999-
2006, the Hb detected only 16 % (Se) of the pregnant
women classified as iron-deficient by the ‘total body iron
model’: {– [log10 (sTfR × 1000 ÷ ferritin) – 2.8229] ÷
0.1207} < 0 mg/Kg [35]. ROC curves in a moderately (0.7 <
AUC≤ 0.9) or less accurate ranges [33] for both indices of
erythrocyte mass and morphology were observed by Tam
et al [10] (versus SF < 20 ng/mL), Casanova et al [9] (versus
SF < 10 ng/mL) and Jaime-Pérez et al [14] (versus SF <
12 ng/mL). On the other hand, Tiwari et al [13] found a
highly accurate (0.9 < AUC< 1.0) curve for Hb, with Se of
91 % and Sp of 79 % for a cutoff of 9.7 g/dL (versus SF <
12 ng/mL), differing from ours and other authors results.
The low diagnostic performance of SF in our study
disagrees with studies comparing SF levels with the iron
contents in the pregnant women’s bone marrow, which
observed a positive correlation [11, 12]. Puolakka et al
[12] found a Se of 72 % for SF < 35 ng/mL and Van den
Broek et al [11] found a Se of 90 %, Sp of 85 % and LR+
of 6.0 for SF < 30 ng/mL, which was more accurate than
serum iron, zinc protoporphyrin, transferrin saturation,
transferrin iron-binding capacity and transferrin recep-
tor. However, these small studies are not enough to val-
idate the SF as a gold-standard for maternal iron-
deficiency. The first one of these two studies occurred
before international standardization of human ferritin
for immune assays [12], and the other one included
many women with HIV and Thalassemia [11].
Studies have shown gaps on standardization of diag-
nostic tests for maternal iron deficiency, precluding high
level evidence [8]. Some differences between results
Table 1 Comparison of sociodemographic, clinical-obstetric,
laboratorial and therapeutic characteristics between iron-






(n 37) (n 102)a
Sociodemographic, clinical-obstetric, laboratorial characteristics at
enrollment
Age (Mean ± SD) 26.3 ± 5.0 25.5 ± 4.7 0.387
Self-assigned ethnicity: n (%) 0.784
Pardo (brown) 23 (62.2) 54 (52.9)
Black 6 (16.2) 20 (19.6)
White 6 (16.2) 19 (18.6)
Others 2 (5.4) 9 (8.8)
BMI Atalah classification:b n (%) 0.094
Underweight 6 (16.2) 21 (20.8)
Health 24 (64.8) 47 (46.5)
Overweight 2 (5.4) 22 (21.8)
Obese 5 (13.5) 11 (10.9)
Educational level: n (%) 0.255
Incomplete primary/middle
school
1 (2.7) 4 (3.9)
Complete primary/middle
school
26 (70.3) 58 (56.9)
Complete high school 10 (27.0) 32 (31.4)
Complete graduation 0 (0.0) 8 (7.8)







Months since the last delivery:
Median (25th;75thcentiles)
71.0 (44.3;90.6) 59.0 (44.8;85.0) 0.720
Nulliparous women: n (%) 21 (56.8) 58 (56.9) 0.991
Women using iron-supplement
for ≥1 month: n (%)
3 (8.1) 20 (19.6) 0.083
Mean of Hb g/dL ± SD 10.1 ± 0.76 10.4 ± 0.58 0.018
Mean of Hb Z-scores ± SD -1.8 ± 0.81 -1.4 ± 0.67 0.005
Serum ferritin (ng/mL): Median
(25th;75thcentiles)
19.0 (9.0;33.0) 28.7 (11.1;53.0) 0.060
Characteristics of the therapeutic test with oral iron
Pregnancy weeks at start iron-
therapy: Mean ± SD
21.6 ± 5.6 23.1 ± 4.6 0.121
Iron-therapy duration (days):
Mean ± SD
52.6 ± 26.4 64.0 ± 26.1 0.025
Iron total doses: n (%) 0.046
1200–1760 mg 2 (5.4) 10 (9.8)
1800–2400 mg 16 (43.2) 22 (21.6)
>2400 mg 19 (51.4) 70 (68.6)
Gastrointestinal symptoms after
starting oral iron: n (%)
29 (78.4) 63 (61.8) 0.054
Hb haemoglobin concentration, R$ current Brazilian coin, SD standard
deviation of 95 %, BMI body mass index
aAmong the not iron-responsive women, one woman had no data on income
and another did not have the BMI
bAtalah et al 1997
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found in previous validation studies and our own may
be due to differences between the tests adopted as refer-
ence standard. While SF and bone marrow reflect the
stored iron [3], the responsiveness to oral iron can re-
flect the physiologic balance between iron needs and in-
testinal absorption [36], and has been considered as a
confirmatory test [3], even in pregnant women [7, 25].
Moreover, conventional criteria based on statistical cut-
off points of erythrocyte indices and SF are static and do
not seem coherent with the dynamic of body iron and
plasma volume throughout pregnancy. However, despite
of therapeutic tests with oral iron having already been
applied in studies with children [37, 38] and with non-
pregnant women [39], we were unable to find reports in
pregnancy.
The reference standard was our main source of limita-
tion, as patient compliance and physiologic changes of Hb
(U-shaped curve of Hb) during pregnancy could bias the
assessment of the therapeutic test with oral iron [26, 40].
From this perspective, gastrointestinal side-effects may in-
fluence whether women genuinely ingested iron pills, and
may cause ascertainment-bias. To handle this issue, we
monitored pill ingestion and registered adherence to an
effective iron dose, as well as losses that would not exert
an important effect on our analyses. In turn, the U-shaped
curve of Hb, if not accounted for, could lead one to incor-
rectly conclude that physiological changes in Hb after a
period of treatment were due to the oral iron [26, 40]. To
correct this curvilinear phenomenon by including the ges-
tational age (at start and end of iron-therapies) paramet-
rically in a linear statistical model might not fit well [26].
On the other hand, a placebo group can be used for this
purpose [1, 41, 42], but not at a real clinical setting.
For these reasons, we assessed the responsiveness to
oral iron, subject by subject, by Hb Z-scores [19, 20],
and then we adopted it as a dependent variable in a re-
gression model to estimate a dose-response effect per
iron pill. The adjusted coefficient of 0.008 Z-score per
pill was robust and agreed with meta-analyzes adjusted
for control groups, which estimate Hb increases of
0.4 g/dL in pregnant women, after a few weeks of low
daily doses of oral iron [1, 42]. Two previous works have
used Hb Z-scores to assess oral iron-therapies during
Table 2 Index-tests (erythrogram and ferritin) and reference-
standard (therapeutic test with oral iron) results (144 pregnant
women)
Response to the therapeutic test with oral iron (increase≥










32 79 111 04
Negative 05 23 28 01




20 48 68 02
Negative 17 54 71 03




22 54 76 01
Negative 15 48 63 04




07 14 21 01
Negative 30 88 118 04




07 13 20 01
Negative 30 89 119 04




12 17 29 03
Negative 25 85 110 02




08 25 33 00
Negative 29 77 106 05




02 05 07 01
Lost or not
performed
02 15 17 00
Negative 33 82 115 04
Total 37 102 139 05
Serum Ferritin
Table 2 Index-tests (erythrogram and ferritin) and reference-




12 25 37 01
Lost or not
performed
02 05 07 00
Negative 23 72 95 04
Total 37 102 139 05
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pregnancy, but both of them aimed to compare intermit-
tent with daily treatments, rather than to estimate a
dose-response effect [26, 43]. The significant per pill ef-
fect in our analysis indicates that we could identify min-
imal therapeutic responses, within the broad period of
iron-therapies in this trial (23–125 days), particularly
because women ingested therapeutic doses [41] in both
groups of iron-responsive and not iron-responsive
anaemia.
Finally, in our study population, if the decision to treat
was based on Hb or SF, half of women would undergo
iron-therapy without hematological benefit or would not
Table 3 Accuracy of erythrogram and ferritin to predict the responsiveness to iron-therapy in 139 pregnant women
Index-tests Sensitivity Specificity Predictive Value + Predictive Value -
% (CI) % (CI) % (CI) % (CI)
Red blood cell count
(<3.8•1012cel/L)
86.5 (72.0;94.1) 22.5 (15.5;31.6) 28.8 (21.2;37.8) 82.1 (64.4;92.1)
HTC
(<32.0 %)
59.5 (43.5;73.6) 47.1 (37.7;56.7) 28.9 (19.9;36.9) 76.2 (64.4;85.0)
Hb
(<10.5 g/dL)
54.0 (38.4;68.9) 52.9 (43.3;68.9) 29.4 (19.9;41.1) 76.1 (64.9;84.5)
MCV
(<81.0 fL)
18.9 (9.5;34.2) 86.3 (78.2;91.6) 33.3 (17.2;54.6) 74.6 (66.0;81.6)
MCH
(<26.0 pg)
18.9 (9.5;34.2) 87.2 (79.4;92.4) 35.0 (18.1;56.7) 74.8 (66.3;81.7)
MCHC
(<32.0 g/dL)
32.4 (19.6;48.5) 83.3 (74.9;89.3) 41.4 (25.5;59.3) 77.3 (68.6;84.1)
RDW 21.6 (11.4;37.2) 75.5 (66.3;82.8) 24.2 (12.8;41.0) 72.6 (63.5;80.2)
(>14.0 %)
Reticulocyte (n = 122)
(<1.0 %)
5.7 (1.58;18.6) 94.2 (87.2;97.5) 28.6 (8.2;64.1) 71.3 (62.4;78.8)
Serum ferritin (n = 132)
(<12.0 ng/mL)
34.3 (20.8;50.8) 74.2 (64.7;81.9) 32.4 (19.6;48.5) 75.8 (66.3;83.3)
CI 95 % Confidence Interval, HTC (haematocrit), Hb (haemoglobin concentration), MCV (mean corpuscular volume), MCH (mean corpuscular haemoglobin), MCHC
(mean corpuscular haemoglobin concentration), RDW (red blood cells distribution width)
Table 4 Accuracy of erythrogram and ferritin to discriminate iron-responsive and not iron-responsive pregnant women (n 139)
Index-tests LR + LR – Diagnostic Odds AUC
Ratio (CI) Ratio (CI) Ratio (CI) Area (CI)
Red blood cell count
(<3.8•1012cel/L)
1.12 (1.08;1.16) 0.60 (0.30;1.19) 1.86 (0.65;5.33) 0.51 (0.40;0.61)
HTC
(<32.0 %)
1.12 (1.02;1.24) 0.86 (0.72;1.03) 1.30 (0.61;2.80) 0.55 (0.44;0.66)
Hb
(<10.5 g/dL)
1.15 (1.01;1.30) 0.87 (0.75;1.01) 1.15 (0.62;2.81) 0.58 (0.47;0.70)
MCV
(<81.0 fL)
1.38 (0.36;5.26) 0.94 (0.88;1.01) 1.47 (0.54;3.98) 0.51 (0.40;0.62)
MCH
(<26.0 pg)
1.48 (0.38;5.73) 0.93 (0.87;0.99) 1.60 (0.58;4.38) 0.57 (0.47; 0.68)
MCHC
(<32.0 g/dL)
1.95 (1.23;3.07) 0.81 (0.75;0.88) 2.40 (1.01;5.69) 0.64 (0.54;0.74)
RDW
(>14.0 %)
0.88 (0.34;2.32) 1.04 (0.96;1.12) 0.85 (0.34;2.10) 0.51 (0.41;0.62)
Reticulocyte (n = 122)
(<1.0 %)
0.99 (0.20;4.89) 1.00 (0.91;1.10) 0.99 (0.18;5.38) 0.58 (0.47;0.68)
Serum ferritin (n = 132)
(<12.0 ng/mL)
1.33 (0.90;1.97) 0.88 (0.80;1.97) 1.50 (0.65;3.46) 0.61 (0.50;0.71)
LR (Likelihood Ratio), AUC (Area Under Receiver Operating Characteristic Curve), CI 95 % (Confidence Interval), HTC (haematocrit), Hb (haemoglobin concentration),
MCV (mean corpuscular volume), MCH (mean corpuscular haemoglobin), MCHC (mean corpuscular haemoglobin concentration), RDW (red blood cells
distribution width)
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receive treatment despite having iron needs. This finding
agrees with the estimate that only half of the global burden
of anaemia can be attributed uniquely to iron-deficiency [4,
44], and that only half of anaemic pregnant women get
cured after taking adequate amounts of iron in clinical trials
[1, 41]. Actually, if the response to the therapeutic test with
oral iron was taken into account, most of the pregnant
women studied would be identified as not iron-responsive.
This result may point towards the presence of other causes
of anaemia and futile treatments, since these women were
treated longer and with higher iron doses. Nevertheless, a
lack of empirical data during pregnancy may bring doubts
about how sensitive to the therapeutic test with oral iron
would be women with severe anaemia, as well as if other
biomarkers could be correlated with iron-responsiveness
more than those we had selected.
Conclusions
Erythrocyte indices and serum ferritin have low ability
to predict and discriminate the iron needs in women
with mild-moderate anaemia at 2nd or 3rd trimesters of
pregnancy. On the other hand, a therapeutic test with
oral iron in low doses may timely identify less iron-
responsive cases. We recommend using Nomograms of
Hb Z-scores as a practical and low-cost tool to normalize
the haemodilution effect on Hb therapeutic changes dur-
ing routinely prenatal care; but they should be built and
validated for each country or world region, as well as
new diagnostic tests for maternal iron-deficiency should
be investigated.
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